Sun Pharma launches lipid disorders drug Ezallor Sprinkle™ in the U.S.
Category: #health  By Pankaj Singh  Date: 2019-07-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sun Pharma launches lipid disorders drug Ezallor Sprinkle™ in the U.S.

Ezallor Sprinkle™ (rosuvastatin) capsules can be indicated for three lipid disorders in conjunction with patient’s diet.

Indian pharma giant, Sun Pharmaceutical Industries Ltd. has recently announced the U.S. launch of Ezallor Sprinkle™ (rosuvastatin) capsules, a drug designed specifically to treat patients with elevated lipid disorders.

According to sources, Ezallor Sprinkle is indicated as an adjunct to diet for treating adults with hypertriglyceridemia, primary dysbetalipoproteinemia (type III hyperlipoproteinemia), and other lipid-lowering treatments like LDL apheresis. It also acts as a monotherapy to lower LDL-C, total cholesterol, and ApoB in patients with homozygous familial hypercholesterolemia.

Speaking on the launch, Abhay Gandhi, CEO, North America, Sun Pharma, said that their firm, with Ezallor Sprinkle, will continue on its commitment to provide a portfolio of alternative formulation products that address the needs of patients facing difficulty in swallowing, which is particularly prevalent among residents in long-term care facilities who cannot swallow.

He said that these patients often encounter more medicinal errors and problems with medication administration compared to long-term care residents who don’t face such swallowing difficulties.

Commenting on the issue, Dr. Chris Chappel, Certified Medical Director, Chappel Group Research & Chappel Senior Care, said that the risk of medication errors increases when patients face difficulty in swallowing due to crushing of medicines that should not be crushed, or from residual medication left in crushing devices.

He said that Ezallor Sprinkle’s formulation will help in administering medication for patients with common elevated lipid disorders, especially in the elderly population.

For the record, Ezallor Sprinkle is developed as an extended-release-coated capsule that can be sprinkled over soft food, can be swallowed as whole, or administered through a nasogastric tube to facilitate long-term, once-daily administration.

It combines with Kapspargo Sprinkle™ extended-release tablets as the second drug in the Sun Pharma portfolio designed specifically for individuals in long-term care.

Reports cite that Ezallor Sprinkle is contraindicated in patients with known hypersensitivity to rosuvastatin, which may include pruritus, urticaria, rash, and angioedema. Moreover, in controlled clinical trials, the most common adverse reactions with rosuvastatin were abdominal pain, asthenia, headache, myalgia, and nausea.

Source Credit: https://www.businesswire.com/news/home/20190714005038/en/Sun-Pharma-Launches-Ezallor-Sprinkle-Rosuvastatin-U.S



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Emergency Care Partners finalizes its merger with Chicago’s IEMS
Emergency Care Partners finalizes its merger with Chicago’s IEMS
By Pankaj Singh

With rising cases of roadside accidents worldwide, the need for emergency medical facilities have increased considerably in recent years. These facilities offer immediate assistance without any appointments, which make...

Zelegent expands to OSA therapeutics with MISH platform acquisition
Zelegent expands to OSA therapeutics with MISH platform acquisition
By Pankaj Singh

  • MISH Technology stands for Minimally Invasive Suspension of the Hyoid and is a novel pre-clinical product line meant to treat obstructive sleep apnea (OSA).
  • SunGen Pharma and Elite Pharmaceuticals file an ANDA with the FDA
    SunGen Pharma and Elite Pharmaceuticals file an ANDA with the FDA
    By Pankaj Singh

    This is the second ANDA filed by both the companies, giving Elite Pharmaceutical the exclusive right to retail the drug.

    Elite Pharmaceuticals, Inc. a pharmaceutica...